Year Published
- 2008 (3) Apply 2008 filter
- (-) Remove 2009 filter 2009
- 2010 (8) Apply 2010 filter
- 2011 (4) Apply 2011 filter
- 2012 (2) Apply 2012 filter
- 2013 (1) Apply 2013 filter
- 2014 (3) Apply 2014 filter
- (-) Remove 2015 filter 2015
- 2016 (4) Apply 2016 filter
- 2017 (4) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (1) Apply 2020 filter
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- (-) Remove Literature Review filter Literature Review
- Portfolio Review (0)
- Research Brief (3) Apply Research Brief filter
Geography
- East Africa Region and Selected Countries (0)
- Global (3) Apply Global filter
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (2) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (1) Apply ASTI filter
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove 2018 filter 2018
- (-) Remove 2009 filter 2009
- (-) Remove 2015 filter 2015
- (-) Remove Research & Development filter Research & Development
- (-) Remove Household Well-Being & Equity filter Household Well-Being & Equity
- (-) Remove Literature Review filter Literature Review
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The literature on poverty’s causes and cures in developing countries posits a variety of contributing factors. Most researchers acknowledge that a sustained exit from poverty is complex and no single causal pathway from poverty to non-poverty exists. In this review, we present a summary framework for categorizing the various theorized pathways out of poverty, and evaluate the empirical evidence for which interventions and resulting outcomes are most frequently and most strongly associated with poverty alleviation. We conducted a literature review on pathways out of poverty for low-income households in developing countries and identified and categorized general strategies and outcomes demonstrated to be empirically associated with poverty alleviation. We organized the general strategies into four asset groups that could be targeted to alleviate poverty: human, natural, built / financial, and social / political. Much of the literature presents positive results on poverty alleviation, but it is difficult to compare across studies because many of the studies were conducted in different countries and at different scales, and use a variety of outcome measures.
We review the current body of literature exploring the theories behind holistic human development measurements and the tradeoffs of different methodologies for the construction of human development indices. Through a systematic review of published and grey literature in the fields of human, international, and economic development we identify 22 current indices that aggregate measures from multiple dimensions of human development. We then analyze these indices to identify tradeoffs related to their unique characteristics and construction methodologies, considering ease of calculation, coverage of different measures of human development, ease of interpretation, comparability, and novelty. The report is accompanied by an appendix of summary tables for each index with further details regarding background information, methodology, index components, and evaluation criteria addressed within the report.
This report reviews the current body of peer-reviewed scholarship exploring the impacts of morbidity on economic growth. This overview seeks to provide a concise introduction to the major theories and empirical evidence linking morbidity – and the myriad different measures of morbidity – to economic growth, which is defined primarily in terms of gross domestic product (GDP) and related metrics (wages, productivity, etc.). Through a systematic review of published manuscripts in the fields of health economics and economic development we further identify the most commonly-used pathways linking morbidity to economic growth. We also highlight the apparent gaps in the empirical literature (i.e., theorized pathways from morbidity to growth that remain relatively untested in the published empirical literature to date).
This report provides a general overview of trends in public and private agricultural research and development (R&D) funding and expenditures in Sub-Saharan Africa (SSA). The request is divided into two sections, covering public funding and private funding. Within each section, relevant data is presented on historical funding patterns, the types of research conducted, and which countries within SSA are financing R&D at the highest level. We find that the majority of growth in African public agricultural research funding took place in the 1960s, when real public spending on agricultural research increased 6% a year. From 1971 to 2000 annual growth averaged 1.4% a year. Public financing of agricultural R&D experienced a moderate shift in the 1990s from bilateral and multilateral donor funding to domestic government financing. The shift varied by country, but donor funding dropped for all SSA countries an average of 10%. Private research and development funding is heavily concentrated in developed countries with the United States and Japan the two biggest spenders. Within SSA, private R&D expenditures comprise 2% of all R&D spending. The main private actors in SSA are companies based in South Africa and Nigeria. The private sector is focused on research areas that involve marketable inputs, such as chemicals, seeds, and machines/
This report present a thorough review of relevant literature regarding labor constraints currently being faced in Sub-Saharan Africa (SSA). The review focuses on the impacts of labor supply issues, particularly as they relate to the use of new technology and management techniques, off farm labor migration, and the impacts of HIV/AIDS. The review is provides a basic breakdown of the different kinds of agricultural labor in SSA, before presenting the evidence on the causes and impact of agricultural labor constraints. Though labor constraints can be relevant on both the demand and supply side, especially for certain groups such as women and youth, our review follows the literature by focusing on the supply side issues. The literature reviewed was written between 1990 and 2008, and includes a combination of reports from government organizations and highly cited journal articles.